Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804777 | 0.89 | KDM4E (0.38) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2804843 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2804778 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2808977 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2806842 | 0.87 | TACR1 (0.43) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2805029 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2810880 | 0.87 | ALDH1A1 (0.44) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL4812170 | 0.86 | SLC6A2 (0.47) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2804641 | 0.86 | KDM4E (0.38) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL2812254 | 0.86 | KDM4E (0.40) | KDM4EALDH1A1LMNAHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1694668-B1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-7652011-B2 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2007-02-15 | — | — | US | disclosed |
| EP-1694668-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005054229-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | TRPV1, IL1B, OPRK1 | KDM4E 1117/4885ALDH1A1 322/4885LMNA 3906/4885 |
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | AQP4, AQP1, IL4I1 | KDM4E 1062/4885ALDH1A1 48/4885LMNA 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.